MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis

Marianne B Løvendorf; John R Zibert; Mette Gyldenløve; Mads A Røpke; Lone Skov

doi:10.1016/j.jdermsci.2014.05.005

MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis

Marianne B Løvendorf, John R Zibert, Mette Gyldenløve, Mads A Røpke, Lone Skov

Department of Clinical Medicine

56 Citations (Scopus)

Abstract

Background: Psoriasis is a systemic inflammatory skin disease. MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that recently have been found in the blood to be relevant as disease biomarkers. Objective: We aimed to explore miRNAs potential as blood biomarkers for psoriasis. Methods: Using microarray and quantitative real-time PCR we measured the global miRNA expression in whole blood, plasma and peripheral blood mononuclear cells (PBMCs) from patients with psoriasis and healthy controls. Results: We identified several deregulated miRNAs in the blood from patients with psoriasis including miR-223 and miR-143 which were found to be significantly upregulated in the PBMCs from patients with psoriasis compared with healthy controls (FCH. =. 1.63, P<. 0.01; FCH. =. 2.18, P<. 0.01, respectively). In addition, miR-223 and miR-143 significantly correlated with the PASI. score (r=. 0.46, P<. 0.05; r=. 0.55, P<. 0.02, respectively). Receiver-operating characteristic analysis (ROC) showed that miR-223 and -143 have the potential to distinguish between psoriasis and healthy controls (miR-223: area under the curve (AUC). =. 0.80, miR-143: AUC. =. 0.75). Interestingly, after 3-5 weeks of treatment with methotrexate following a significant decrease in psoriasis severity, miR-223 and miR-143 were significantly downregulated in the PBMCs from patients with psoriasis. Conclusion: We suggest that changes in the miR-223 and miR-143 expressions in PBMCs from patients with psoriasis may serve as novel biomarkers for disease activity in psoriasis; however, further investigations are warranted to clarify their specific roles.

Original language	English
Journal	Journal of Dermatological Science
Volume	75
Issue number	2
Pages (from-to)	133-139
Number of pages	7
ISSN	0923-1811
DOIs	https://doi.org/10.1016/j.jdermsci.2014.05.005
Publication status	Published - Aug 2014

Keywords

Adolescent
Adult
Aged
Aged, 80 and over
Area Under Curve
Case-Control Studies
Female
Gene Expression Profiling
Genetic Markers
Genetic Testing
Humans
Immunosuppressive Agents
Male
Methotrexate
MicroRNAs
Middle Aged
Oligonucleotide Array Sequence Analysis
Predictive Value of Tests
Psoriasis
ROC Curve
Real-Time Polymerase Chain Reaction
Severity of Illness Index
Time Factors
Treatment Outcome
Young Adult

Access to Document

10.1016/j.jdermsci.2014.05.005

Cite this

@article{5936c4b2426c4487a92997faaae11468,

title = "MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis",

abstract = "Background: Psoriasis is a systemic inflammatory skin disease. MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that recently have been found in the blood to be relevant as disease biomarkers. Objective: We aimed to explore miRNAs potential as blood biomarkers for psoriasis. Methods: Using microarray and quantitative real-time PCR we measured the global miRNA expression in whole blood, plasma and peripheral blood mononuclear cells (PBMCs) from patients with psoriasis and healthy controls. Results: We identified several deregulated miRNAs in the blood from patients with psoriasis including miR-223 and miR-143 which were found to be significantly upregulated in the PBMCs from patients with psoriasis compared with healthy controls (FCH. =. 1.63, P<. 0.01; FCH. =. 2.18, P<. 0.01, respectively). In addition, miR-223 and miR-143 significantly correlated with the PASI. score (r=. 0.46, P<. 0.05; r=. 0.55, P<. 0.02, respectively). Receiver-operating characteristic analysis (ROC) showed that miR-223 and -143 have the potential to distinguish between psoriasis and healthy controls (miR-223: area under the curve (AUC). =. 0.80, miR-143: AUC. =. 0.75). Interestingly, after 3-5 weeks of treatment with methotrexate following a significant decrease in psoriasis severity, miR-223 and miR-143 were significantly downregulated in the PBMCs from patients with psoriasis. Conclusion: We suggest that changes in the miR-223 and miR-143 expressions in PBMCs from patients with psoriasis may serve as novel biomarkers for disease activity in psoriasis; however, further investigations are warranted to clarify their specific roles.",

keywords = "Adolescent, Adult, Aged, Aged, 80 and over, Area Under Curve, Case-Control Studies, Female, Gene Expression Profiling, Genetic Markers, Genetic Testing, Humans, Immunosuppressive Agents, Male, Methotrexate, MicroRNAs, Middle Aged, Oligonucleotide Array Sequence Analysis, Predictive Value of Tests, Psoriasis, ROC Curve, Real-Time Polymerase Chain Reaction, Severity of Illness Index, Time Factors, Treatment Outcome, Young Adult",

author = "L{\o}vendorf, {Marianne B} and Zibert, {John R} and Mette Gyldenl{\o}ve and R{\o}pke, {Mads A} and Lone Skov",

year = "2014",

month = aug,

doi = "10.1016/j.jdermsci.2014.05.005",

language = "English",

volume = "75",

pages = "133--139",

journal = "Journal of Dermatological Science",

issn = "0923-1811",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis

AU - Løvendorf, Marianne B

AU - Zibert, John R

AU - Gyldenløve, Mette

AU - Røpke, Mads A

AU - Skov, Lone

PY - 2014/8

Y1 - 2014/8

N2 - Background: Psoriasis is a systemic inflammatory skin disease. MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that recently have been found in the blood to be relevant as disease biomarkers. Objective: We aimed to explore miRNAs potential as blood biomarkers for psoriasis. Methods: Using microarray and quantitative real-time PCR we measured the global miRNA expression in whole blood, plasma and peripheral blood mononuclear cells (PBMCs) from patients with psoriasis and healthy controls. Results: We identified several deregulated miRNAs in the blood from patients with psoriasis including miR-223 and miR-143 which were found to be significantly upregulated in the PBMCs from patients with psoriasis compared with healthy controls (FCH. =. 1.63, P<. 0.01; FCH. =. 2.18, P<. 0.01, respectively). In addition, miR-223 and miR-143 significantly correlated with the PASI. score (r=. 0.46, P<. 0.05; r=. 0.55, P<. 0.02, respectively). Receiver-operating characteristic analysis (ROC) showed that miR-223 and -143 have the potential to distinguish between psoriasis and healthy controls (miR-223: area under the curve (AUC). =. 0.80, miR-143: AUC. =. 0.75). Interestingly, after 3-5 weeks of treatment with methotrexate following a significant decrease in psoriasis severity, miR-223 and miR-143 were significantly downregulated in the PBMCs from patients with psoriasis. Conclusion: We suggest that changes in the miR-223 and miR-143 expressions in PBMCs from patients with psoriasis may serve as novel biomarkers for disease activity in psoriasis; however, further investigations are warranted to clarify their specific roles.

AB - Background: Psoriasis is a systemic inflammatory skin disease. MicroRNAs (miRNAs) are a class of small non-coding RNA molecules that recently have been found in the blood to be relevant as disease biomarkers. Objective: We aimed to explore miRNAs potential as blood biomarkers for psoriasis. Methods: Using microarray and quantitative real-time PCR we measured the global miRNA expression in whole blood, plasma and peripheral blood mononuclear cells (PBMCs) from patients with psoriasis and healthy controls. Results: We identified several deregulated miRNAs in the blood from patients with psoriasis including miR-223 and miR-143 which were found to be significantly upregulated in the PBMCs from patients with psoriasis compared with healthy controls (FCH. =. 1.63, P<. 0.01; FCH. =. 2.18, P<. 0.01, respectively). In addition, miR-223 and miR-143 significantly correlated with the PASI. score (r=. 0.46, P<. 0.05; r=. 0.55, P<. 0.02, respectively). Receiver-operating characteristic analysis (ROC) showed that miR-223 and -143 have the potential to distinguish between psoriasis and healthy controls (miR-223: area under the curve (AUC). =. 0.80, miR-143: AUC. =. 0.75). Interestingly, after 3-5 weeks of treatment with methotrexate following a significant decrease in psoriasis severity, miR-223 and miR-143 were significantly downregulated in the PBMCs from patients with psoriasis. Conclusion: We suggest that changes in the miR-223 and miR-143 expressions in PBMCs from patients with psoriasis may serve as novel biomarkers for disease activity in psoriasis; however, further investigations are warranted to clarify their specific roles.

KW - Adolescent

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Area Under Curve

KW - Case-Control Studies

KW - Female

KW - Gene Expression Profiling

KW - Genetic Markers

KW - Genetic Testing

KW - Humans

KW - Immunosuppressive Agents

KW - Male

KW - Methotrexate

KW - MicroRNAs

KW - Middle Aged

KW - Oligonucleotide Array Sequence Analysis

KW - Predictive Value of Tests

KW - Psoriasis

KW - ROC Curve

KW - Real-Time Polymerase Chain Reaction

KW - Severity of Illness Index

KW - Time Factors

KW - Treatment Outcome

KW - Young Adult

U2 - 10.1016/j.jdermsci.2014.05.005

DO - 10.1016/j.jdermsci.2014.05.005

M3 - Journal article

C2 - 24909097

SN - 0923-1811

VL - 75

SP - 133

EP - 139

JO - Journal of Dermatological Science

JF - Journal of Dermatological Science

IS - 2

ER -

MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis

Abstract

Keywords

Access to Document

Fingerprint

Cite this